Literature DB >> 32314173

Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease.

Mark Parta1, Dianne Hilligoss2, Corin Kelly2, Nana Kwatemaa2, Narda Theobald2, Christa S Zerbe2, Steven M Holland2, Harry L Malech2, Elizabeth M Kang2.   

Abstract

PURPOSE: Haploidentical related donor (HRD) transplantation was performed in 7 recipients with chronic granulomatous disease (CGD) who had no matched-related or unrelated donor.
METHODS: Peripheral blood cell (PBC) products were used with a conditioning regimen consisting of low-dose cyclophosphamide, fludarabine, total body irradiation, and busulfan. Graft-versus-host disease (GVHD) prophylaxis consisted of high-dose post-transplant cyclophosphamide and sirolimus. Recipients were ages 14-26 years, and 3 had severe infections active at transplant.
RESULTS: All 7 recipients achieved full engraftment with complete donor chimerism early in the post-transplant period. Acute GVHD occurred in all cases and was grade 3 or steroid refractory in 3. Two patients with steroid-refractory GVHD died. Three patients with severe infectious complications active at transplant, 1 Nocardia pneumonia and 2 extensive invasive fungal infections), survived and were cured of their infection at last follow-up. Bacterial disease occurred post-transplant in all recipients, and viral infections/reactivation were common, including 4 cases of BK virus-associated hemorrhagic cystitis.
CONCLUSIONS: Seven patients with CGD achieved rapid and full-donor engraftment from HRDs utilizing PBCs and a conditioning regimen with PTCy and sirolimus GVHD prophylaxis. However, the incidence of grade 3 and steroid-refractory GVHD was high and led to 2 deaths. Patients with active infections at transplant had successful transplant courses and were cured of their disease. Although there was an initial success with this regimen, the cumulative experience does not support its use in CGD due to an unacceptable rate of severe GVHD.

Entities:  

Keywords:  Chronic granulomatous disease; graft-versus-host disease; haploidentical; post-transplant cyclophosphamide

Mesh:

Substances:

Year:  2020        PMID: 32314173      PMCID: PMC7507116          DOI: 10.1007/s10875-020-00772-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  9 in total

1.  Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).

Authors:  Amandine Fayard; Elisabeth Daguenet; Didier Blaise; Patrice Chevallier; Hélène Labussière; Ana Berceanu; Ibrahim Yakoub-Agha; Gérard Socié; Amandine Charbonnier; Felipe Suarez; Anne Huynh; Mélanie Mercier; Claude-Eric Bulabois; Bruno Lioure; Sylvain Chantepie; Yves Beguin; Jean-Henri Bourhis; Jean-Valère Malfuson; Laurence Clément; Régis Peffault de la Tour; Jérôme Cornillon
Journal:  Bone Marrow Transplant       Date:  2019-02-15       Impact factor: 5.483

2.  Haploidentical related donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for DOCK8 deficiency.

Authors:  Alexandra F Freeman; Nirali N Shah; Mark Parta; Helen C Su; Alessandra Brofferio; Irma Gradus-Pizlo; Sabah Butty; Thomas E Hughes; David E Kleiner; Daniele Avila; Theo Heller; Heidi H Kong; Steven M Holland; Dennis D Hickstein
Journal:  J Allergy Clin Immunol Pract       Date:  2016-09-15

3.  Haploidentical hematopoietic stem cell transplantation for a case with X-linked chronic granulomatous disease.

Authors:  Ling Zhou; Lu-Jia Dong; Zhi-Yong Gao; Xin-Jian Yu; Dao-Pei Lu
Journal:  Pediatr Transplant       Date:  2016-11-25

4.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Authors:  Mohamed L Sorror; Paul J Martin; Rainer F Storb; Smita Bhatia; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Christopher Davis; H Joachim Deeg; Stephanie J Lee; David G Maloney; Brenda M Sandmaier; Frederick R Appelbaum; Theodore A Gooley
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

5.  Haploidentical stem cell transplantation in a boy with chronic granulomatous disease.

Authors:  A Regueiro-García; S Fariña-Nogueira; J Á Porto-Arceo; J M Couselo-Sánchez
Journal:  Allergol Immunopathol (Madr)       Date:  2018-01-17       Impact factor: 1.667

6.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

7.  Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in a Patient with Chronic Granulomatous Disease and Active Infection: A First Report.

Authors:  Mark Parta; Dianne Hilligoss; Corin Kelly; Nana Kwatemaa; Narda Theobald; Harry Malech; Elizabeth M Kang
Journal:  J Clin Immunol       Date:  2015-10-09       Impact factor: 8.317

8.  Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.

Authors:  Mark Parta; Nirali N Shah; Kristin Baird; Hind Rafei; Katherine R Calvo; Thomas Hughes; Kristen Cole; Meg Kenyon; Bazetta Blacklock Schuver; Jennifer Cuellar-Rodriguez; Christa S Zerbe; Steven M Holland; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-03       Impact factor: 5.742

Review 9.  Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art.

Authors:  James A Connelly; Rebecca Marsh; Suhag Parikh; Julie-An Talano
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-09       Impact factor: 3.164

  9 in total
  1 in total

Review 1.  Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.

Authors:  Elizabeth M Kang
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.